AI Article Synopsis
Article Abstract
Objective: To assess the efficacy of pretreatment with mifepristone before misoprostol, compared with misoprostol alone, for termination of pregnancy after a fetal death in the second trimester.
Methods: This prospective, double blind, placebo-controlled trial randomized women requiring a termination of pregnancy after fetal death between 14 and 28 weeks of gestation to placebo or 200 mg mifepristone orally 24-48 hours before the termination of pregnancy with misoprostol (400 micrograms every 6 hours vaginally for women at 24 weeks of gestation or less, and 200 micrograms every 4 hours vaginally for women at 24 weeks of gestation or more). Based on a median labor with misoprostol alone in the second trimester of 13 hours, a sample size of 116 women per group was planned to compare the primary outcome of time from administration of misoprostol to delivery. The trial was ceased after 66 women were enrolled secondary to prolonged time to achieve recruitment.
Results: From April 2013 to November 2016, 66 women were randomized (34 to placebo and 32 to mifepristone). There were no differences in the characteristics between the two groups. The median time for the primary outcome of administration of misoprostol to delivery in the placebo group was 10.5 hours, compared with 6.8 hours in the treatment group (hazard ratio 2.41 95% CI 1.39-4.17, P=.002). Women in the placebo group required more doses of misoprostol (3.4 vs 2.1, P=.002) and more misoprostol overall (1,181.8 micrograms, vs 767.7 micrograms, P=.003). There was no difference in maternal complications between the two groups. Women in the mifepristone group reported improved perception of the procedure.
Conclusion: The sequential use of mifepristone and misoprostol for the termination of pregnancy after fetal deaths between 14 and 28 weeks of gestation reduces the time to delivery, compared with the use of misoprostol alone, with no worsening of maternal complications.
Clinical Trial Registration: Australian New Zealand Clinical Trials Registry, ACTRN12612000884808.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/AOG.0000000000004344 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic Variants Associated With Preeclampsia and Maternal Serum sFLT1 Levels.
Hypertension
December 2024
Department of Obstetrics and Gynaecology, School of Clinical Medicine, University of Cambridge, United Kingdom. (J.A.M., U.S., F.G., E.C., D.S.C.-J., G.C.S.S.).
Background: Elevated maternal serum sFLT1 (soluble fms-like tyrosine kinase 1) has a key role in the pathophysiology of preeclampsia. We sought to determine the relationship between the maternal and fetal genome and maternal levels of sFLT1 at 12, 20, 28, and 36 weeks of gestational age (wkGA).
Methods: We studied a prospective cohort of nulliparous women (3968 mother-child pairs).
Executive functioning challenges of adolescents born extremely and very preterm.
Front Psychol
December 2024
Department of Paediatrics, University of Otago Christchurch, Christchurch, New Zealand.
Background: Children born very preterm (VPT; <32 weeks) are at increased risk of executive functioning (EF) difficulties. But less is known about the nature and extent of these executive difficulties during late adolescence, particularly across multiple EF domains and in response to varying degrees of executive demand.
Methods: Using data from a prospective longitudinal study, this paper describes the EF profiles of 92 VPT and 68 full-term (FT) adolescents at age 17 years.
Case report: A successful live birth after fertilization and embryo transfer in a patient with endometrial cancer who was treated conservatively.
Front Oncol
December 2024
Department of Obstetrics and Gynecology, School of Medicine, Nankai University, Tianjin, China.
Objective: To describe a patient conceiving with fertilization and embryo transfer(IVF-ET) after conservative treatment of early stage endometrial cancer.
Patient: A 31-year-old multiparous woman diagnosed with highly-differentiated (G1) endometrial adenocarcinoma (grade IA).
Interventions: After four courses of conservative treatment each followed by hysteroscopic biopsy and endometrial curettage,assisted reproductive technology was performed.
Dynamic changes of gut microbiota between the first and second trimester for women with gestational diabetes mellitus and their correlations with BMI: a nested cohort study in China.
Front Microbiol
December 2024
Center of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen, China.
Introduction: Gut microbiota (GM) has been implicated in gestational diabetes mellitus (GDM), yet longitudinal changes across trimesters remain insufficiently explored.
Methods: This nested cohort study aimed to investigate GM alterations before 24 weeks of gestation and their association with GDM. Ninety-three Chinese participants provided fecal samples during the first and second trimesters.
A sequential explanatory mixed method study of maternal and fetal outcome in gestational diabetes mellitus using Diabetes in Pregnancy Study Group India (DIPSI) test in Puducherry.
J Family Med Prim Care
November 2024
Department of Community Medicine, Sri Manakula Vinayagar Medical College and Hospital, Puducherry, India.
Background: Gestational diabetes mellitus in pregnancy is associated with polyhydramnios, macrosomia, and shoulder dystocia, and it also increases maternal and perinatal mortality.
Methods: This sequential explanatory mixed-method study was conducted for six months. All the pregnant women attending the outpatient department of the Obstetrics and Gynaecology Department at 24-28 weeks of gestation were subjected to universal screening with 75 gms of glucose and 2 hours of plasma glucose >140 mgs% is taken for diagnosis (according to DIPSI guidelines).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!